183 related articles for article (PubMed ID: 25645830)
1. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
[TBL] [Abstract][Full Text] [Related]
2. Clofazimine for the Treatment of Mycobacterium kansasii.
Srivastava S; Gumbo T
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
[No Abstract] [Full Text] [Related]
3. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.
Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2016 Jun; 60(6):3779-85. PubMed ID: 27067317
[TBL] [Abstract][Full Text] [Related]
4. Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.
Singh S; Gumbo T; Boorgula GD; Shankar P; Heysell SK; Srivastava S
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068722. PubMed ID: 35976006
[TBL] [Abstract][Full Text] [Related]
5. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
Srivastava S; Boorgula GD; Wang JY; Huang HL; Howe D; Gumbo T; Heysell SK
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0232021. PubMed ID: 35315686
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii.
Boorgula GD; Singh S; Shankar P; Gumbo T; Heysell SK; Srivastava S
Tuberculosis (Edinb); 2023 Jan; 138():102289. PubMed ID: 36512853
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T
Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.
Chapagain M; Gumbo T; Heysell SK; Srivastava S
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690646
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.
Ferro BE; Srivastava S; Deshpande D; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2016 May; 60(5):2895-900. PubMed ID: 26926649
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
12. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i30-i35. PubMed ID: 28922807
[TBL] [Abstract][Full Text] [Related]
13. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.
Ferro BE; Srivastava S; Deshpande D; Sherman CM; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1242-8. PubMed ID: 26643339
[TBL] [Abstract][Full Text] [Related]
14. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
Srivastava S; Pasipanodya JG; Heysell SK; Boorgula GD; Gumbo T; McShane PJ; Philley JV
J Glob Antimicrob Resist; 2022 Mar; 28():71-77. PubMed ID: 34933140
[TBL] [Abstract][Full Text] [Related]
15. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i48-i53. PubMed ID: 28922809
[TBL] [Abstract][Full Text] [Related]
16. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
17. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium.
Deshpande D; Srivastava S; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2010 May; 54(5):1728-33. PubMed ID: 20231389
[TBL] [Abstract][Full Text] [Related]
18. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
[TBL] [Abstract][Full Text] [Related]
19. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
20. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
